Replimune Secures FDA Accelerated Approval for TUDRIQEV in Advanced Melanoma
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune received FDA accelerated approval for TUDRIQEV, its first commercial product, for advanced melanoma. The approval transforms the company's outlook, enabling a U.S. launch within 60 days and addressing a critical unmet need.
Updates
· Benzinga — Shares fell 5% premarket, possibly on sell-the-news or dilution concerns given the recent S-3/A shelf registration for 25.1M shares by Baker Brothers.
Key Events · Product Development and Regulatory · REPL
-
FDA Accelerated Approval of TUDRIQEV
The FDA approved TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on anti-PD-1 therapy, based on a 24.2% ORR and median DOR of 14.1 months from the IGNYTE trial.
-
First Commercial Product Launch
Replimune expects to ship TUDRIQEV in approximately 60 days, targeting ~10,000 addressable patients in the U.S. and positioning it as the first oncolytic viral combination therapy approved for this indication.
-
Confirmatory Trial Requirement
Continued approval is contingent on verification of clinical benefit in the ongoing Phase 3 IGNYTE-3 trial, which is enrolling patients and will assess overall survival as the primary endpoint.
-
Financial and Strategic Impact
The approval provides a path to first revenue, addressing the company's going concern warning and cash runway only into Q1 2027, and validates the RPx platform for future pipeline expansion.
Analysis · REPL · Life Sciences
The FDA has granted accelerated approval to Replimune's lead oncolytic immunotherapy, TUDRIQEV, for advanced melanoma patients who have progressed on anti-PD-1 therapy. This marks the company's first approved product, validating its RPx platform and propelling Replimune from a clinical-stage biotech to a commercial-stage company. The approval arrives just days after a positive 10-3 advisory committee vote and despite earlier FDA staff concerns, representing a dramatic turnaround. With an addressable U.S. patient population of approximately 10,000 and a planned launch within 60 days, the decision fundamentally reshapes the company's revenue prospects and survival outlook—especially critical given the going concern warning and a cash runway that extends only into Q1 2027.
At the time of this filing, REPL was trading at $12.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.50 to $13.90. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.